Get the Stockscreener App
1.62
1.25%
0.02
After Hours:
1.56
-0.06
-3.70%
Biorestorative Therapies Inc stock is traded at $1.62, with a volume of 13,195.
It is up +1.25% in the last 24 hours and down -34.15% over the past month.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
See More
Previous Close:
$1.60
Open:
$1.59
24h Volume:
13,195
Relative Volume:
0.03
Market Cap:
$11.21M
Revenue:
$149.50K
Net Income/Loss:
$-6.96M
P/E Ratio:
-1.1912
EPS:
-1.36
Net Cash Flow:
$-6.37M
1W Performance:
+7.28%
1M Performance:
-34.15%
6M Performance:
-4.14%
1Y Performance:
+23.66%
1-Day Range:
$1.551
$1.62
1-Week Range:
$1.4632
$1.68
52-Week Range:
$1.03
$2.55
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
1.62 | 11.21M | 149.50K | -6.96M | -6.37M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies (NASDAQ:BRTX) Trading 3.6% Higher – Should You Buy? - Defense World
Will BioRestorative's Cell Therapy Revolutionize The Spine Treatment Forte? - RTTNews
Reviewing Eastgate Biotech (OTCMKTS:ETBI) and BioRestorative Therapies (OTCMKTS:BRTX) - Armenian Reporter
BioRestorative Therapies Says FDA Clears BRTX-100 Trial in Chronic Cervical Discogenic Pain - Marketscreener.com
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain - The Manila Times
BioRestorative announces FDA clearance of IND for Phase 2 BRTX-100 trial - TipRanks
First-Ever Stem Cell Treatment for Neck Pain Gets FDA Green LightWhat Makes BRTX-100 Revolutionary? - StockTitan
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update - Yahoo Finance
What Will BioRestorative Reveal About Its Stem Cell Therapies on February 27? - StockTitan
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline - The Manila Times
Comparing Quipt Home Medical (NASDAQ:QIPT) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program - GlobeNewswire
Can This FDA-Fast-Tracked Therapy Finally Solve Chronic Back Pain? Phase 2 Data Shows Promise - StockTitan
Contrasting Quipt Home Medical (NASDAQ:QIPT) and BioRestorative Therapies (NASDAQ:BRTX) - Defense World
Roth Capital Has Pessimistic Outlook of BRTX FY2028 Earnings - Defense World
BioRestorative Therapies Presents at Orthopaedic Research Society Annual MeetingBioRestorative Therapies, Inc. recently made an announcement through a press release on February 10, 2025, regarding its participation in the Orthopaedic Research Societ - Defense World
BioRestorative Therapies Issues Regulation FD Disclosure - TipRanks
BRTX-100 Front and Center at ORS 2025 - GlobeNewswire
Game-Changing Clinical Data: BRTX-100 Achieves 73% Pain Relief in Chronic Back Pain Trial - StockTitan
BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Shift From Loss To Profit - Yahoo Finance
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading Down 0.9%Here's Why - MarketBeat
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting - ACCESS Newswire
With BioRestorative Therapies Up 18%, Insider Buyers Count Their Returns - Simply Wall St
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Up 0.7%Here's Why - MarketBeat
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Up 0.7% – Here’s What Happened - Defense World
BioRestorative Therapies, Inc. announced that it has received $1 million in funding - Marketscreener.com
Pleasing Signs As A Number Of Insiders Buy BioRestorative Therapies Stock - Yahoo Finance
BioRestorative Therapies (OTCMKTS:BRTX) Share Price Passes Above Fifty Day Moving Average – Here’s What Happened - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Hits New 12-Month HighTime to Buy? - MarketBeat
BioRestorative Therapies Announces Notice of Allowance of - GlobeNewswire
BioRestorative Therapies Secures Key European Patent for Revolutionary Obesity Treatment Technology - StockTitan
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program - Yahoo Finance
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial - Nasdaq
BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain TrialEli Lilly (NYSE:LLY), BioRestorative Therapies (NASDAQ:BRTX) - Benzinga
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market - Nasdaq
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Analyzing American Caresource (OTCMKTS:GNOW) & BioRestorative Therapies (NASDAQ:BRTX) - Defense World
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
BioRestorative Therapies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioRestorative Therapies earnings beat by $0.31, revenue fell short of estimates - Investing.com Canada
BioRestorative Therapies Q3 2024 Financial Update - TipRanks
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function - Benzinga
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data - OrthoSpineNews
BioRestorative's BRTX-100 Shows 100% Success Rate in Early Back Pain Trial Data | BRTX Stock News - StockTitan
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
BioRestorative Therapies Enters at-the-Market Offering Agreement with Rodman & Renshaw LLC - Defense World
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):